Purpose: Several endoscopic techniques have become available in the past decade for eradication of Barrett's dysplasia and intramucosal cancer (IMC). These include radiofrequency ablation (RFA), endoscopic mucosal resection (EMR), cryotherapy and argon plasma coagulation (APC). These therapies are highly successful in most patients for eradication of dysplasia but some patients continue to have small areas of residual Barrett's on endoscopy or biopsies. A minority of patients do not respond or continue to progress to severe dysplasia or cancer. Our aim is to evaluate for factors which predict complete eradication of Barrett's metaplasia. Methods: Review of prospectively collected database of patients who underwent endoscopic therapy for Barrett's dysplasia or IMC from 2006 to 2011. Patients who underwent EMR only or currently undergoing therapy are excluded. Demographic features such as age, race, sex, BMI, alcohol use, smoking, diabetes, hypertension, hyperlipidemia, medication use such as aspirin, NSAIDS, statins, anti-hypertensive agents, fundoplication were analyzed. Endoscopic data including length of Barrett's segment in the initial endoscopy, hiatal hernia size, number of endoscopies, interventions during the endoscopy and biopsy results were reviewed. Results: There were 102 patients who met the inclusion criteria. There was complete eradication of Barrett's in 50 patients (49%). There was Barrett's without dysplasia in 47 patients (46%). 5 patients had persistent dysplasia one of whom developed HGD (5%). There were no significant differences between two groups in terms of age, gender, race, smoking, alcohol use, BMI, DM, hypertension, hyperlipidemia, medication use, hiatal hernia size or baseline biopsies. The results are summarized in Table 1. On multivariable logistic analysis, shorter Barrett's length in the initial endoscopy was associated an increasing odds ratio of eradication of metaplasia (OR: 0.85, CI 0.74, 0.99, p=0.031 for every 1cm decrease).Table: No Caption available.Conclusion: Shorter length of Barrett's segment is associated with complete eradication of Barrett's metaplasia. In the minority of patients when APC was used for ablation of residual Barrett's, it lead to a better treatment response.